Eli Lilly & Co. (LLY)
1142.85
-7.00
(-0.61%)
USD |
NYSE |
Oct 02, 16:00
1144.07
+1.22
(+0.11%)
After-Hours: 20:00
Eli Lilly Enterprise Value : 1.122T for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 1.122T |
| October 01, 2026 | 1.129T |
| September 30, 2026 | 1.135T |
| September 29, 2026 | 1.161T |
| September 28, 2026 | 1.161T |
| September 25, 2026 | 1.160T |
| September 24, 2026 | 1.159T |
| September 23, 2026 | 1.130T |
| September 22, 2026 | 1.148T |
| September 21, 2026 | 1.143T |
| September 18, 2026 | 1.131T |
| September 17, 2026 | 1.131T |
| September 16, 2026 | 1.117T |
| September 15, 2026 | 1.116T |
| September 14, 2026 | 1.118T |
| September 11, 2026 | 1.096T |
| September 10, 2026 | 1.103T |
| September 09, 2026 | 1.104T |
| September 08, 2026 | 1.104T |
| September 04, 2026 | 1.128T |
| September 03, 2026 | 1.138T |
| September 02, 2026 | 1.138T |
| September 01, 2026 | 1.138T |
| August 31, 2026 | 1.135T |
| August 28, 2026 | 1.152T |
| Date | Value |
|---|---|
| August 27, 2026 | 1.153T |
| August 26, 2026 | 1.166T |
| August 25, 2026 | 1.207T |
| August 24, 2026 | 1.220T |
| August 21, 2026 | 1.228T |
| August 20, 2026 | 1.218T |
| August 19, 2026 | 1.251T |
| August 18, 2026 | 1.200T |
| August 17, 2026 | 1.160T |
| August 14, 2026 | 1.157T |
| August 13, 2026 | 1.184T |
| August 12, 2026 | 1.195T |
| August 11, 2026 | 1.190T |
| August 10, 2026 | 1.206T |
| August 07, 2026 | 1.162T |
| August 06, 2026 | 1.168T |
| August 05, 2026 | 1.147T |
| August 04, 2026 | 1.096T |
| August 03, 2026 | 1.102T |
| July 31, 2026 | 1.128T |
| July 30, 2026 | 1.133T |
| July 29, 2026 | 1.185T |
| July 28, 2026 | 1.195T |
| July 27, 2026 | 1.173T |
| July 24, 2026 | 1.172T |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 644.86B |
| Merck & Co., Inc. | 403.00B |
| Pfizer Inc. | 210.23B |
| Bristol Myers Squibb Co. | 158.92B |
| Structure Therapeutics, Inc. | 634.14M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 7.095B |
| Revenue (Quarterly) | 22.97B |
| Total Expenses (Quarterly) | 15.88B |
| EPS Diluted (Quarterly) | 7.939 |
| Gross Profit Margin (Quarterly) | 85.78% |
| Profit Margin (Quarterly) | 30.88% |
| Earnings Yield | 2.58% |
| Operating Earnings Yield | 3.82% |
| Normalized Earnings Yield | 2.984 |